
"But interestingly, talking to sort of key opinion leaders in the space, they suggest that really cost is no longer the issue. It is effectively cheap enough. And it's now just about 40% of the total cost of the workflow for doing a diagnostic"
Graeme Bencke and Mikhail Zverev discuss decreasing costs in genomic sequencing in the short clip below 👇
Tune into the full discussion on Genomics: the next chapter 👉://vimeo.com/1179557046
⚠️ Warning: Capital at Risk. Professional Investors Only.
#AmatiGlobal #Genomics #healthcare #diagnostics #DNA #genesequencing #investing #investments #fundresearch #investmentmanagement #fundmanagement #wealthmanagement #financial
English




